JP6951971B2 - 親水性薬物の標的化された送達 - Google Patents

親水性薬物の標的化された送達 Download PDF

Info

Publication number
JP6951971B2
JP6951971B2 JP2017514562A JP2017514562A JP6951971B2 JP 6951971 B2 JP6951971 B2 JP 6951971B2 JP 2017514562 A JP2017514562 A JP 2017514562A JP 2017514562 A JP2017514562 A JP 2017514562A JP 6951971 B2 JP6951971 B2 JP 6951971B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
alkyl
aqueous
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527593A (ja
JP2017527593A5 (enExample
Inventor
ロコト、イゴール
Original Assignee
ダブル ボンド ファーマシューティカル アクチボラグ
ダブル ボンド ファーマシューティカル アクチボラグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダブル ボンド ファーマシューティカル アクチボラグ, ダブル ボンド ファーマシューティカル アクチボラグ filed Critical ダブル ボンド ファーマシューティカル アクチボラグ
Publication of JP2017527593A publication Critical patent/JP2017527593A/ja
Publication of JP2017527593A5 publication Critical patent/JP2017527593A5/ja
Application granted granted Critical
Publication of JP6951971B2 publication Critical patent/JP6951971B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017514562A 2014-09-10 2015-09-09 親水性薬物の標的化された送達 Active JP6951971B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1400427-9 2014-09-10
SE1400427 2014-09-10
PCT/SE2015/000055 WO2016039678A1 (en) 2014-09-10 2015-09-09 Targeted delivery of hydrophilic drugs

Publications (3)

Publication Number Publication Date
JP2017527593A JP2017527593A (ja) 2017-09-21
JP2017527593A5 JP2017527593A5 (enExample) 2018-07-05
JP6951971B2 true JP6951971B2 (ja) 2021-10-20

Family

ID=55459328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514562A Active JP6951971B2 (ja) 2014-09-10 2015-09-09 親水性薬物の標的化された送達

Country Status (11)

Country Link
US (2) US10034838B2 (enExample)
EP (1) EP3191138B1 (enExample)
JP (1) JP6951971B2 (enExample)
KR (1) KR20170054459A (enExample)
CN (1) CN107073129B (enExample)
AU (1) AU2015316252A1 (enExample)
CA (1) CA2958820A1 (enExample)
EA (1) EA033526B1 (enExample)
IL (1) IL250637A0 (enExample)
MX (1) MX2017003049A (enExample)
WO (1) WO2016039678A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426228A1 (en) * 2016-03-07 2019-01-16 Double Bond Pharmaceutical AB Targeted delivery of hydrophilic drugs to lung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008599A1 (en) * 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6384081B2 (en) * 1998-10-09 2002-05-07 Charles L. Berman Treatment of diseases of the eye characterized by the formation of metalloproteinase
CN101134119A (zh) 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
GB2415904B (en) 2005-02-07 2006-10-25 Chiron Corp Preparing aldesleukin for pharmaceutical use
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009100222A1 (en) 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
CN101327190B (zh) * 2008-07-29 2011-04-27 北京大学 一种供注射用的抗肿瘤长循环靶向脂质体
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
KR101728011B1 (ko) 2013-01-23 2017-04-20 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 덱스트란 메타크릴레이트 및 생체적합성 음이온성 고분자를 포함하는 생분해성 마이크로 비드 및 이의 제조방법

Also Published As

Publication number Publication date
EP3191138A4 (en) 2018-06-20
IL250637A0 (en) 2017-04-30
JP2017527593A (ja) 2017-09-21
EP3191138A1 (en) 2017-07-19
CA2958820A1 (en) 2016-03-17
EP3191138B1 (en) 2024-05-29
EA033526B1 (ru) 2019-10-31
US10034838B2 (en) 2018-07-31
MX2017003049A (es) 2017-05-23
WO2016039678A1 (en) 2016-03-17
US20170239192A1 (en) 2017-08-24
US20190046462A1 (en) 2019-02-14
KR20170054459A (ko) 2017-05-17
EP3191138C0 (en) 2024-05-29
CN107073129A (zh) 2017-08-18
CN107073129B (zh) 2021-10-15
AU2015316252A1 (en) 2017-03-09
US10973772B2 (en) 2021-04-13
EA201790272A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
Soares et al. Polymer-hybrid nanoparticles: Current advances in biomedical applications
Baig et al. Current status of nanomaterial-based treatment for hepatocellular carcinoma
Morsy et al. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers
Li et al. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia
Kamel et al. Inhalable dual-targeted hybrid lipid nanocore–protein shell composites for combined delivery of genistein and all-trans retinoic acid to lung cancer cells
Xu et al. Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy
Lu et al. Reduction-responsive chemo-capsule-based prodrug nanogel for synergistic treatment of tumor chemotherapy
Wang et al. Supramolecularly engineered phospholipids constructed by nucleobase molecular recognition: upgraded generation of phospholipids for drug delivery
de la Mata et al. Carbosilane dendritic nanostructures, highly versatile platforms for pharmaceutical applications
Li et al. Low density lipoprotein-inspired nanostructured lipid nanoparticles containing pro-doxorubicin to enhance tumor-targeted therapeutic efficiency
Raut et al. Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications
WO2015138992A1 (en) Mitochondrial delivery of 3-bromopyruvate
Wang et al. Investigating the crucial roles of aliphatic tails in disulfide bond-linked docetaxel prodrug nanoassemblies
Huang et al. Development of curcumin-loaded galactosylated chitosan-coated nanoparticles for targeted delivery of hepatocellular carcinoma
Chen et al. Glutathione-scavenging natural-derived ferroptotic nano-amplifiers strengthen tumor therapy through aggravating iron overload and lipid peroxidation
CN112933046A (zh) 一种阿霉素前药主动载药脂质体及其制备方法和应用
CN115368436A (zh) 一种肽基铂类自组装纳米前药及其制备方法和应用
Tarin et al. Targeted delivery of elesclomol using a magnetic mesoporous platform improves prostate cancer treatment both in vitro and in vivo
Chen et al. Efficacy assessment of glycyrrhetinic acid-modified liposomes loaded with doxorubicin hydrochloride and cucurbitine B for synergistic treatment of hepatocellular carcinoma
Gad et al. Novel approaches of solid lipid nanoparticles as drug carrier
Khoshnood et al. Liposome/AZIF-8 Janus nanoplatforms: Promising nanocarriers for improving chemotherapeutic outcomes in breast cancer treatment
MXPA06010950A (es) Formulaciones en nano-particulas de compuestos de platino.
US10973772B2 (en) Targeted delivery of hydrophilic drugs
CN107233314B (zh) 一种具有双靶区同时递药效果的复合磷脂热敏脂质体及其制备方法和应用
CN118239999A (zh) 一种基于胆固醇与二乙基二硫代氨基甲酸酯（dtc）的双硫仑前药的制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190507

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200313

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200317

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200515

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200519

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201106

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210325

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210721

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210804

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210902

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210927

R150 Certificate of patent or registration of utility model

Ref document number: 6951971

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250